Advertisement

Tumor Biology

, Volume 37, Issue 9, pp 11799–11804 | Cite as

The roles of serum PDCD5 in circulating CD133 positive cells of the patients with gastric cancer

Original Article

Abstract

Cancer stem cells are responsible for the development, metastasis, recurrence, and drug resistance of cancer. More and more studies exhibited that the circulating CD133+ cells is a marker for the prognosis of various malignancies. Programmed cell death protein 5 (PDCD5) can promote apoptosis in different tumor cell types in response to various stimuli. However, the impact of PDCD5 on circulating CD133+ cells of gastric cancer patients remains unclear. In this study, we detected serum PDCD5 level in blood samples of the patients with gastric cancer by using ELISA. MTT assay, sphere assay, and wound healing assay were used to test the anti-tumor effects of rhPDCD5 on CD133+ cells in vitro. Lower serum levels of PDCD5 protein were identified in the gastric cancer patients that with CD133+ fraction more than 1.6 %. No difference between healthy controls and the gastric cancer patients that with CD133+ fraction less than 1.6 %. Serum PDCD5 was correlated with the favorable prognosis of patients with gastric cancer. In the last, we confirmed that rhPDCD5 could induce apoptosis, and inhibit the proliferation, colony formation, and mobility of CD133+ cells in vitro by suppressing MEK/ERK pathway. Serum PDCD5 could be considered as a potential drug for the gastric cancer patients with circulating CD133+ cells.

Keywords

Gastric cancer Circulating CD133+ cells PDCD5 Proliferation Prognosis 

Notes

Acknowledgments

This study was supported by National Natural Scientific Foundation of China (No. 81502558) and Talents Introduction Projects of Liaoning Medical University.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Sampieri K, Fodde R. Cancer stem cells and metastasis. Semin Cancer Biol. 2012;22:187–93.CrossRefPubMedGoogle Scholar
  2. 2.
    Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol. 2011;32:425–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Liu JF, Xia P, Hu WQ, Wang D, Xu XY. Aldehyde dehydrogenase 1 expression correlates with clinicopathologic features of patients with breast cancer: a meta-analysis. Int J Clin Exp Med. 2015;8:8425–32.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Wang W, Dong LP, Zhang N, Zhao CH. Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis. Int J Clin Exp Med. 2014;7:5059–66.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Nosrati A, Naghshvar F, Khanari S. Cancer stem cell markers CD44, CD133 in primary gastric adenocarcinoma. Int J Mol Cell Med. 2014;3:279–86.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Xia P, Song CL, Liu JF, Wang D, Xu XY. Prognostic value of circulating CD133+ cells in patients with gastric cancer. Cell Prolif. 2015;48:311–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Liu H, Wang Y, Zhang Y, Song Q, Di C, Chen G, et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem Biophys Res Commun. 1999;254:203–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Fu DZ, Cheng Y, He H, Liu HY, Liu YF. PDCD5 expression predicts a favorable outcome in patients with hepatocellular carcinoma. Int J Oncol. 2013;43:821–30.PubMedGoogle Scholar
  9. 9.
    Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539–48.CrossRefPubMedGoogle Scholar
  10. 10.
    Spinola M, Meyer P, Kammerer S, Falvella FS, Boettger MB, Hoyal CR, et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J Clin Oncol. 2006;24:1672–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhu W, Li Y, Gao L. Cisplatin in combination with programmed cell death protein 5 increases antitumor activity in prostate cancer cells by promoting apoptosis. Mol Med Rep. 2015;11:4561–6.PubMedGoogle Scholar
  12. 12.
    Park SY, Choi HK, Choi Y, Kwak S, Choi KC, Yoon HG. Deubiquitinase OTUD5 mediates the sequential activation of PDCD5 and p53 in response to genotoxic stress. Cancer Lett. 2015;357:419–27.CrossRefPubMedGoogle Scholar
  13. 13.
    Xiao J, Li G, Hu J, Qu L, Ma D, Chen Y. Anti-inflammatory effects of recombinant human PDCD5 (rhPDCD5) in a rat collagen-induced model of arthritis. Inflammation. 2015;38:70–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Xiao J, Liu W, Chen Y, Deng W. Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis. J Neuroinflammation. 2015;12:117.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Li X, Huang JP, Ding J. Apoptosis and expressions of PDCD5 and Caspase-3 in renal tissues of children with lupus nephritis. Zhonghua Er Ke Za Zhi. 2005;43:517–20.PubMedGoogle Scholar
  16. 16.
    Wang Y, Wang GH, Zhang QY. Determination of PDCD5 in peripheral blood serum of cancer patients. Chin J Cancer Res. 2011;23:224–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Joosse SA, Gorges TM, Klaus P. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7:1–11.CrossRefGoogle Scholar
  18. 18.
    D’Angelica MI. Circulating CD133: a promising biomarker, but what are we measuring? Ann Surg Oncol. 2012;19:351–2.CrossRefPubMedGoogle Scholar
  19. 19.
    Nadal R, Ortega FG, Salido M, Lorente JA, Rodríguez-Rivera M, Delgado-Rodríguez M, et al. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer. 2013;133:2398–407.CrossRefPubMedGoogle Scholar
  20. 20.
    Tseng JY, Yang CY, Yang SH, Lin JK, Lin CH, Jiang JK. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients. J Surg Res. 2015;199:362–70.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang J, Guan Z, Ge Z. Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-α and disease activity in patients with rheumatoid arthritis. Biomarkers. 2013;18:155–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen Y, Zou Z, Xu A, Liu Y, Pan H, Jin L. Serum programmed cell death protein 5 (PDCD5) levels is upregulated in liver diseases. J Immunoassay Immunochem. 2013;34:294–304.CrossRefPubMedGoogle Scholar
  23. 23.
    Fu DZ, Cheng Y, He H, Liu HY, Liu YF. Recombinant human PDCD5 exhibits an antitumor role in hepatocellular carcinoma cells via clathrin-dependent endocytosis. Mol Med Rep. 2015;12:8135–40.PubMedGoogle Scholar
  24. 24.
    Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2011;13:39–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120:3397–406.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Han XR, Sun Y, Bai XZ. The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells. Cell Signal. 2012;24:1713–21.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Histology and Embryology, College of Basic Medical ScienceLiaoning Medical UniversityJinzhouChina
  2. 2.Department of Pathophysiology, College of Basic Medical ScienceChina Medical UniversityShenyangPeople’s Republic of China
  3. 3.Department of RadiotherapyCenter Hospital of HandanHandanChina
  4. 4.Department of Cell Biology, College of Basic Medical ScienceLiaoning Medical UniversityJinzhouChina
  5. 5.Department of Cell BiologyBasic Medical College of Liaoning Medical UniversityJinzhouPeople’s Republic of China

Personalised recommendations